Target intelligence / Profile preview

General transcription factor IIi pseudogene 23 (GTF2IP23)

Target: GTF2IP23
Molecular classification: Pseudogene, Non-coding RNA, Regulatory RNA (antisense transcript, based on recent research[1]), Related to transcription factor

Overview

General transcription factor IIi pseudogene 23 (GTF2IP23) is a non-coding pseudogene related to the functional gene GTF2I. GTF2IP23 produces an antisense RNA transcript that can negatively regulate its host gene's expression (GTF2I) and, in breast cancer cells, promotes cellular proliferation and migration. Unlike canonical targets such as receptors or enzymes, GTF2IP23 does not produce a protein and is not druggable. It is primarily of research interest as a regulator of gene expression at the RNA level, and its upregulation has been associated with breast cancer.[1]

Other names: GTF2IP23General transcription factor IIi pseudogene 23通用转录因子Ⅱi假基因23

Mechanism of action

None known. There is only mechanistic inference from its regulation of GTF2I, not direct drug targeting[1].

Biological functions

Negative regulation of the GTF2I mRNA expression (the functional gene)[1]Regulation of cell proliferation and migration in breast cancer, possibly via RNA-RNA interaction effects[1]No protein function; its role is mediated through regulatory nucleic acid mechanisms

Disease associations

Cancer (Breast cancer: GTF2IP23 is upregulated; promotes proliferation and migration of cancer cells[1])Other disease roles: Unclear; literature focuses primarily on breast cancer

Biomarkers

Potential candidate as a biomarker for breast cancer due to its upregulation in tumor tissues[1]Not a validated clinical biomarker

Beyond the preview

Go deeper on General transcription factor IIi pseudogene 23 (GTF2IP23).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on General transcription factor IIi pseudogene 23 (GTF2IP23).

Explore the full profile